What is the evidence that early therapeutic anticoagulation improves survival in patients with portomesenteric venous thrombosis compared with delayed treatment

What is known

- The corpus supports prompt/immediate anticoagulation as the mainstay of treatment for portomesenteric venous thrombosis (PMVT), associated with high recanalization rates and low morbidity. ^1–4

What is unknown / caveats

- There is no head-to-head evidence isolating early versus delayed anticoagulation for a survival endpoint in PMVT - The supporting studies are single-arm retrospective cohorts and narrative algorithms, not comparisons of treatment timing against a mortality outcome.

## References

1. Kayal M, Radcliffe M, Plietz M, Rosman A, Greenstein A, Khaitov S, Sylla P, Dubinsky MC. Portomesenteric Venous Thrombosis in Patients Undergoing Surgery for Medically Refractory Ulcerative Colitis. Inflamm Bowel Dis. 2020;26:283-288. PMID: 31372644.

2. PMID: 25159636. (metadata not in corpus)

3. Allaix ME, Krane MK, Zoccali M, Umanskiy K, Hurst R, Fichera A. Postoperative portomesenteric venous thrombosis: lessons learned from 1,069 consecutive laparoscopic colorectal resections. World J Surg. 2014;38:976-84. PMID: 24240673.

4. Okada T, Sasaki F, Minagawa N, Naito S, Kobayashi R, Kubota M, Todo S. Postoperative portal and splenic vein thrombosis in children: identification of risk factors. Pediatr Surg Int. 2005;21:918-21. PMID: 16189676.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._